Insulet Announces Leadership Changes as CTO Mark Field Departs

Insulet Corporation, a leader in tubeless insulin pump technology, has announced significant changes to its executive team. The company's Chief Technology Officer (CTO), Mark Field, has left the organization to pursue other opportunities, marking another high-profile departure in recent years.

New Acting CTO Appointed Amid Transition

Effective immediately, Amit Guliani, Insulet's group vice president of software engineering, has been appointed as the acting CTO. This swift transition underscores the company's commitment to maintaining continuity in its technological leadership.

Mark Field, who joined Insulet in 2019 and became the company's first CTO in 2023, was responsible for overseeing engineering, cybersecurity, digital and data services, and system architecture. To facilitate a smooth transition, Insulet intends to enter into a consulting agreement with Field, who will also receive severance benefits.

Recent Executive Reshuffling at Insulet

This latest change follows a series of leadership transitions at Insulet:

• In 2022, former CEO Shacey Petrovic stepped down, with board member Jim Hollingshead assuming the role.
• Last year, Ana Maria Chadwick became the new CFO, replacing Wayde McMillan, who left to join 3M's healthcare spinoff, Solventum.

Despite these changes, Insulet has maintained strong performance, reporting double-digit revenue growth last year with total earnings of $2.1 billion.

Continued Innovation and Market Expansion

Amidst the leadership changes, Insulet has achieved significant milestones:

• The company secured an expanded indication for its Omnipod insulin patch pump, now approved for use by individuals with Type 2 diabetes.
• This broadened market access is expected to contribute to Insulet's continued growth and market presence.

As Insulet navigates this transition, the company has announced that a search for a permanent CTO is underway, signaling its commitment to strengthening its technological capabilities and maintaining its position as an innovator in diabetes care.